Compass Therapeutics (CMPX) Invested Capital: 2023-2025
Historic Invested Capital for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $209.6 million.
- Compass Therapeutics' Invested Capital rose 51.46% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.6 million, marking a year-over-year increase of 51.46%. This contributed to the annual value of $125.2 million for FY2024, which is 15.69% down from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Invested Capital is $209.6 million, which was up 124.89% from $93.2 million recorded in Q2 2025.
- Compass Therapeutics' Invested Capital's 5-year high stood at $209.6 million during Q3 2025, with a 5-year trough of $93.2 million in Q2 2025.
- For the 3-year period, Compass Therapeutics' Invested Capital averaged around $148.4 million, with its median value being $148.5 million (2023).
- Over the last 5 years, Compass Therapeutics' Invested Capital had its largest YoY gain of 51.46% in 2025, and its largest YoY loss of 36.21% in 2025.
- Compass Therapeutics' Invested Capital (Quarterly) stood at $148.5 million in 2023, then declined by 15.69% to $125.2 million in 2024, then skyrocketed by 51.46% to $209.6 million in 2025.
- Its Invested Capital was $209.6 million in Q3 2025, compared to $93.2 million in Q2 2025 and $110.3 million in Q1 2025.